Securities code: 300497 securities abbreviation: Jiangxi Fushine Pharmaceutical Co.Ltd(300497) Announcement No.: 2022-006
Jiangxi Fushine Pharmaceutical Co.Ltd(300497)
Announcement on the appointment of deputy general manager of the company
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Jiangxi Fushine Pharmaceutical Co.Ltd(300497) (hereinafter referred to as “the company”) convened the 27th meeting of the third board of directors on January 6, 2022, deliberated and adopted the proposal on the appointment of deputy general manager of the company. Due to the needs of the company’s operation and development, in accordance with the company law, the guidelines for the standardized operation of companies listed on the gem of Shenzhen Stock Exchange, the articles of association and other relevant provisions, the board of directors agreed to appoint Mr. Wei Haipeng as the deputy general manager of the company after being nominated by the general manager of the company and reviewed and approved by the nomination committee of the board of directors, The term of office starts from the date of deliberation and approval of the current board of directors to the date of expiration of the term of office of the third board of directors. The independent directors of the company expressed their independent opinions on this matter.
See the attachment for the resume of Mr. Wei Haipeng.
It is hereby announced.
Jiangxi Fushine Pharmaceutical Co.Ltd(300497)
Board of directors
January 6, 2022
enclosure:
Resume of Mr. Wei Haipeng
Mr. Wei Haipeng, Chinese nationality, member of the Communist Party of China, has no right of permanent residence abroad. Born in 1976, graduated from Zhejiang University of technology, engineer. From July 1999 to September 2006, he worked in Zhejiang Hisun Pharmaceutical Co.Ltd(600267) and successively served as workshop Technician, technical director and workshop director; From September 2006 to July 2009, he served as the production manager of Taizhou Nanjing Hicin Pharmaceutical Co.Ltd(300584) Co., Ltd; From July 2009 to October 2016, served as deputy general manager and executive deputy general manager of Jiangxi Ruyi Technology Development Co., Ltd; From October 2016 to June 2021, served as the general manager of Weifang Aotong Pharmaceutical Co., Ltd; From June 2021 to January 2022, he served as the general manager of Jingde town Fuxiang Life Technology Co., Ltd.
As of the disclosure date of this announcement, Mr. Wei Haipeng directly holds 5000 shares of the company and subscribes 75000 shares of the company through the Jiangxi Fushine Pharmaceutical Co.Ltd(300497) phase I employee stock ownership plan. There is no affiliated relationship with shareholders holding more than 5% of the company’s shares, directors, supervisors and senior managers of the company; Not punished by the CSRC and other relevant departments or the stock exchange; It does not belong to the dishonest person to be executed; His qualifications comply with the company law, the guidelines for the standardized operation of companies listed on the gem of Shenzhen Stock Exchange, the articles of association and other relevant provisions.
